Skip to main content
Premium Trial:

Request an Annual Quote

Horizon, Univ. of Liverpool to Collaborate on Cancer Biomarkers

NEW YORK (GenomeWeb News) – Horizon Discovery today said that it has inked a research collaboration with the University of Liverpool to use the firm's tools to identify and validate cancer drug targets and biomarkers for personalized cancer therapy and diagnostics.

The partners will utilize Horizon's X-Man cell lines and have access to the firm's panel of over 150 genetically-defined isogenic disease models, said Horizon. The company will work with Michael Clague of the University of Liverpool to identify unique protein biomarker signatures.

The aim of the collaboration is to accelerate the search for patient-focused drug targets and theranostic biomarkers.

"Professor Clague represents a leading researcher on protein regulation mechanisms and is ideally placed to define novel targets and biomarkers that will help maximize the benefits of targeted therapies in cancer patients," Horizon CEO Chris Torrance said in a statement.

Financial and further terms of the alliance were not disclosed.